Revance Therapeutics, Inc. Sustainability Profile
Revance Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on innovative aesthetic and therapeutic solutions. Founded in 2011, Revance has made significant strides in the industry, particularly with its proprietary DaxibotulinumtoxinA injection, which offers a unique, long-lasting alternative to traditional neuromodulators. With a strong presence in the aesthetic and therapeutic sectors, Revance is committed to advancing patient care through its cutting-edge products. The company has achieved notable milestones, including successful clinical trials and regulatory approvals, positioning itself as a key player in the competitive landscape of biotechnology. Revance's dedication to innovation and quality sets it apart, making it a trusted name in the field.
DitchCarbon Score
How does Revance Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Revance Therapeutics, Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Revance Therapeutics, Inc.'s reported carbon emissions
Revance Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reduce greenhouse gas emissions at this time. As a current subsidiary, Revance's climate initiatives and emissions data may be influenced by its corporate family structure. However, no specific cascading data from parent organisations or related entities has been provided. This indicates that Revance Therapeutics, Inc. is still in the early stages of developing its climate strategy and emissions reporting. In the broader context of the biotechnology industry, companies are increasingly recognising the importance of sustainability and climate commitments. Revance may need to align with industry standards and expectations to enhance its environmental performance and transparency in the future.
How Carbon Intensive is Revance Therapeutics, Inc.'s Industry?
How Carbon Intensive is Revance Therapeutics, Inc.'s Location?
Revance Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Revance Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
